Vascular Cell Preconditioning for Transduction Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating peripheral artery disease, such as systemic administration of growth factors and local gene transfer, have failed to provide significant therapeutic benefits, and there is a need for alternative strategies that enhance angiogenesis and vascular cell therapy.
Innovation Solution
Preconditioning human smooth muscle and endothelial cells with DEAE-Dextran and transducing them with retroviral or lentivirus constructs encoding VEGF165 or Angiopoietin-1, followed by hypothermal preservation, to improve transduction efficiency and cell viability for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vascular cells are transduced with retroviral or lentivirus constructs encoding VEGF165 or Angiopoietin-1, then angiogenic potential is enhanced, but transduction efficiency and cell viability are reduced
Solution Approach 1:
The patent applies preliminary action by preconditioning vascular cells with DEAE-Dextran before transduction. This pre-treatment modifies cell surface properties to enhance subsequent viral entry and transduction efficiency, while also preparing cells for better survival after the stressful transduction process. The preconditioning step is performed ahead of time to optimize both transduction efficiency and maintain cell viability.
Solution Approach 2:
The patent employs parameter changes by optimizing the concentration of DEAE-Dextran (testing ranges from 0.0625 mg/ml to 1.0 mg/ml) and the duration of preconditioning (1-5 minutes). By systematically varying these parameters, the invention identifies optimal conditions that maximize transduction efficiency while preserving cell viability, thus resolving the contradiction between enhanced angiogenic potential and maintained cell productivity.
2Productivity
If DEAE-Dextran concentration is increased to enhance transduction, then transduction rate improves, but cell proliferation and viability deteriorate
Solution Approach 1:
The patent systematically varies the DEAE-Dextran concentration parameter (testing 0.0625, 0.125, 0.25, 0.5, 1.0 mg/ml) to identify the optimal range that maximizes transduction rate while maintaining cell proliferation. The invention discovers that lower concentrations (0.125-0.5 mg/ml) are more effective than higher concentrations (1.0 mg/ml), thus resolving the contradiction by finding the optimal parameter value.
Solution Approach 2:
The patent applies partial action by using sub-optimal concentrations of DEAE-Dextran (0.125-0.5 mg/ml) rather than maximum concentrations (1.0 mg/ml). This partial application of the preconditioning agent is sufficient to enhance transduction efficiency while avoiding the cytotoxic effects that would compromise cell proliferation and viability.
3Productivity
If transduction duration is extended to improve gene delivery, then transduction efficiency increases, but cell stress and mortality increase
Solution Approach 1:
The patent applies preliminary action by performing DEAE-Dextran preconditioning before transduction. This pre-treatment strengthens cell membranes and prepares cellular machinery for efficient viral uptake, allowing for shorter transduction durations that maintain high transduction efficiency while reducing the duration of cell stress and associated mortality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in enhanced transduction rates, proliferation, and viability of vascular cells, making them suitable for angiogenic cell therapy and treatment of vascular diseases.
Implementation Method 1
The preconditioning comprises contacting the SM cells with between 0.125 and 0.9 mg/ml DEAE-Dextran
Implementation Method 2
followed by hypothermal preservation, to improve transduction efficiency and cell viability for therapeutic use
Data Source
AI summary
Methods and compositions for pre-conditioning, transduction and/or hypothermic preservation of vascular cells transduced with nucleic acid constructs for expressing pro-angiogenic factors are provided. Also provided are uses of such cells in therapy.